

Table 1: King County STD r	norbidity			
	2018		2019	
	2018Q3	YTD	2019Q3	YTD
Gonorrhea (GC)*	1079	3305	1261	3462
GC: MSM	538	1748	682	1839
Urethral GC	144	493	168	490
Rectal GC	256	834	321	860
Pharyngeal GC	292	894	365	978
GC: Women^	225	705	274	780
GC: MSW^	200	531	201	559
GC: Transgender‡	10	27	8	25
Chlamydia (CT)*	2799	7824	2675	7651
CT: Men	1435	3916	1349	3764
CT: Women	1355	3873	1315	3850
CT: Transgender‡	8	29	8	25
Total Syphilis (all stages)*	221	682	234	774
Primary and secondary	100	291	69	265
Early latent	77	255	110	310
Late + unk duration	44	136	52	196
Early syphilis: MSM	145	466	154	493
Early syphilis: Women	11	22	7	20
Early syphilis: MSW	9	29	8	29
Early syphilis: Transgender	1	6	1	6
Congenital syphilis	0	0	3	3

^{*}Column may not equal total due to missing gender or sexual preference data

Trends in STD Morbidity


Figure 1: Quarterly King County STD morbidity, women and MSW a. Women (note different scales) 300 1600 1400 1200 250 Gonorrhea cases Chlamydia cases 200 1000 150 600 100 400 50 200 0 201801 201802 201703 b. MSW (note different scales)** 225 1200 200 1000 Chlamydia cases 175 Gonorrhea cases 150 125 800 600 100 75 400 50 25 200 201803 701802 - Gonorrhea - Chlamydia

STD Case Counts

Table 2: King County newly diagnosed HIV cases*					
	2018		2019		
	2018Q2	YTD	2019Q2	YTD	
Total†	69	150	65	126	
MSM	32	79	38	77	
Women	19	40	13	23	
MSW	2	6	2	4	
Transgender‡	0	0	2	4	

^{*} Data shown for prior quarter due to reporting delay.

Trends in STD Morbidity



Primary & secondary

* Includes primary, secondary, and early latent syphilis cases

[^] Genital tract infection


[‡] Transgender identity relies on reporting from medical providers and Partner Services Interviews. Data presented here are a potential undercount.

[†] Column may not equal total due to missing sexual preference data.

[‡] Transgender identity relies on review of information documented in medical records and obtained through Partner Services Interviews. Data presented here are a potential undercount.




Figure 3: HIV testing among PHSKC STD Clinic patients, MSM (note different scales)




* Denominator includes patients who reported never testing or negative/unknown results

HIV testing should be performed annually on low-risk MSM and quarterly on high-risk MSM^a.

Figure 4: Percentage of King County residents with a bacterial STD tested for HIV (excludes HIV+ residents)



Anyone diagnosed with a bacterial STD should be tested for HIV.



Alert value = Minimum Inhibitory Concentration (MIC, lowest antibiotic concentration needed to halt bacterial growth) is higher than preset thresholds^c. Alert value MICs represent decreased susceptibility to an antibotic but may not represent resistance.

Footnotes and Abbreviations:

**Chlamydia case data on gender of sex partners and anatomic site of infection are incomplete for these time periods

MSM = Men who have sex with men

MSW = Men who have sex with women

^aHigh-risk = MSM with any one of the following in the prior year: diagnosis of a bacterial STD, methamphetamine or popper use, ≥10 sex partners (anal or oral), or unprotected anal sex with a partner of unknown or discordant HIV status

 $\label{low-risk} \mbox{Low-risk} = \mbox{sexually active MSM who do not meet high-risk criteria}$

^bSURRG = Strengthening the U.S. Response to Resistant Gonorrhea Surveillance, supported by the Centers for Disease Control and Prevention

^cAlert values:

Ceftriaxone MIC ≥ 0.125 μg/ml Azithromycin MIC ≥ 2.0 μg/ml Cefixime MIC ≥ 0.25 μg/ml

Table 3: SURRG isolates with alert values for cephalosporins (ceph) or azithromycin (azi)

2019Q3 170 136 22 10 2		YTD 434 366 54 22 2 Ceph N (%)
136 22 10 2		366 54 22 2
22 10 2		54 22 2 Ceph
10 2 Ceph		22 2 Ceph
2 Ceph		2 Ceph
Ceph		Ceph
•		•
NI /0/	s) N (%)	N (%)
) N (%	., (/-9/	١٠ /
2) 2 (1)) 41 (9)	5 (1)
3) 2 (1)) 36 (10) 5 (1)
0 (0)	3 (6)	0 (0)
0 (0)	0 (0)	0 (0)
) 2 (100	0 (0)
	0 (0	` ' ` '